Miplyffa 62 MG (equivalent to 100 MG arimoclomol citrate) Oral Capsule
- RxCUI
- 2694302
- RxNorm name
- Miplyffa 62 MG (equivalent to 100 MG arimoclomol citrate) Oral Capsule
- Display name
- Miplyffa 62 MG (equivalent to 100 MG arimoclomol citrate) Oral Capsule
- Full name
- Miplyffa 62 MG (equivalent to 100 MG arimoclomol citrate) Oral Capsule
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:00
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| MIPLYFFA | ARIMOCLOMOL CITRATE | Acer Therapeutics Inc. | 5feffc0e-453d-47fa-91dd-38d4952309bc | 2026-03-18 | Warnings, Adverse reactions | 2694302 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 5feffc0e-453d-47fa-91dd-38d4952309bc | Miplyffa 62 MG (equivalent to 100 MG arimoclomol citrate) Oral Capsule | SY | 5 | These highlights do not include all the information needed to use MIPLYFFA ® safely and effectively. See full prescribing information for MIPLYFFA. MIPLYFFA (arimoclomol) capsules, for oral use Initial U.S. Approval: 2024 | 20260318 |
| 5feffc0e-453d-47fa-91dd-38d4952309bc | MIPLYFFA 62 MG Oral Capsule | PSN | 5 | These highlights do not include all the information needed to use MIPLYFFA ® safely and effectively. See full prescribing information for MIPLYFFA. MIPLYFFA (arimoclomol) capsules, for oral use Initial U.S. Approval: 2024 | 20260318 |
| 5feffc0e-453d-47fa-91dd-38d4952309bc | arimoclomol 62 MG Oral Capsule [Miplyffa] | SBD | 5 | These highlights do not include all the information needed to use MIPLYFFA ® safely and effectively. See full prescribing information for MIPLYFFA. MIPLYFFA (arimoclomol) capsules, for oral use Initial U.S. Approval: 2024 | 20260318 |